Cardiol Therapeutics (CRDL) Liabilities and Shareholders Equity (2020 - 2026)

Cardiol Therapeutics has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $22.9 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 29.1% year-over-year to $22.9 million; the trailing twelve-month figure through Mar 2026 stood at $63.6 million (down 12.38% YoY), and the FY2025 full-year result was $16.9 million, down 25.74% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $22.9 million, up from $16.9 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $62.7 million in Q1 2022, with the low at $9.4 million in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $30.1 million across 5 years, with a median of $23.1 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 107.93% — and 2024, when it plunged 60.01%.
• Cardiol Therapeutics' Liabilities and Shareholders Equity stood at $45.7 million in 2022, then slumped by 41.01% to $27.0 million in 2023, then declined by 15.39% to $22.8 million in 2024, then fell by 25.74% to $16.9 million in 2025, then soared by 35.21% to $22.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $22.9 million (Q1 2026), $16.9 million (Q4 2025), and $9.4 million (Q3 2025), per Business Quant data.